post-chemotherapy setting for metastatic seminoma. However, false positive results can be a problem. We sought to identify a new methodology to interpret FDG-PET scans using a more objective approach to reduce false positive results.
INTRODUCTION AND OBJECTIVES: Retroperitoneal lymph node dissection (RPLND) is an important component of the management of testicular germ cell tumor (GCT) but carries significant morbidity. Herein we describe our updated experience with a midline extraperitoneal (EP) approach to RPLND for seminomatous and nonseminomatous GCT that minimizes perioperative morbidity.
METHODS: 122 consecutive patients from an IRB approved database underwent RPLND from 2010-2015. Patients requiring aortic resection, retrocrural dissection or access to intraperitoneal disease were excluded. The remaining 69 patients underwent midline EP-RPLND. All post-chemotherapy (PC) cases underwent bilateral template dissection; all primary cases underwent extended ipsilateral templates. Perioperative and long-term outcomes were analyzed and a descriptive analysis using SAS was performed.
RESULTS: 68 patients underwent midline EP-RPLND successfully (98.6%). Median age was 28 years. On pre-operative imaging the size of retroperitoneal mass or lymphadenopathy was <2 cm in 29 patients, 2-5 cm in 15 patients, and >5 cm in 24 patients, of which 19 were >10cm. 3 patients underwent cavectomy. Median EBL was 325 mL (IQR: 200-612.5). Median number of lymph nodes (LN) resected was 36 (IQR: 24.5-49); median number of positive nodes was 1 (IQR: 0-4). Median return of bowel function was 2 days (IQR: 1-2) and LOS was 3 days (IQR: 3-4). There were no cases of ileus. 11 patients (16.2%) had 30-day complications: 6 (55%) were Clavien grade 1, 5 (45%) were grade 2. There was 1 long-term complication (1.5%), which was grade 3b. Antegrade ejaculation rates were 91.6% in the primary group and 96.8% in the PC group.
CONCLUSIONS: Midline EP-RPLND can be performed safely without compromising completeness of resection. This approach is associated with a faster return of bowel function, lower rates of ileus and shorter LOS. INTRODUCTION AND OBJECTIVES: Penile cancer (PC) is a rare and potentially disfiguring disease. There have been great strides made to improve cancer control, as well as to decrease treatmentassociated morbidities. We present our outcomes using penile sparing surgery (PSS) for the treatment of PC in the largest cohort known to date.
Source of
METHODS: 1439 patients were retrospectively identified to have undergone PSS for PC from July 2000 to June 2015 at five international institutions of excellence. PSS consisted of laser ablation, wide local excision, circumcision, and partial/total glansectomy. Patient demographics and clinical characteristics were summarized using descriptive statistics. Univariate analyses were performed using the chisquare test for categorical variables. Kaplan Meier survival curves were applied to determine overall recurrence free survival (RFS) as well RFS stratified by pathologic stage and surgical intervention.
RESULTS: Median patient age of our cohort was 63 years old. Median patient follow up was 40 months. 23.9% of all patients recurred after PSS. 5 year RFS by pT stage was Ta/Tis: 58.0%, T1: 55.5%, and T2: 49.8%. RFS for all patients undergoing PSS was 55.6%( 1 year: 77.3%, 2 year: 67.3%, 5 year: 55.6%). Treatment modality (p¼0.056) and pT stage (p¼0.99) did not significantly correlate with RFS at 5 years. Patients with higher pT tumors underwent more aggressive interventions (p <0.001).
CONCLUSIONS: PSS is indicated for appropriately selected patients with PC. Treatment modality and pT stage were not significant predictors of RFS. Close follow-up remains a critical component of all treatment considerations.
INTRODUCTION AND OBJECTIVES:
Cisplatin-based chemotherapy (CBC) is a cornerstone in the treatment of advanced stage testicular cancer (TC). Since its introduction it has led to excellent survival rates and as TC usually is a cancer of young men, most patients live to experience significant short-and long-term side effects. These include infertility, cardiovascular disease, and sensomotoric impairment due to oto-and neurotoxicity. Meanwhile little is known on retinal toxicity associated with CBC. We therefore sought to outline potential morphological and functional retinal alterations in CBC treated patients.
METHODS: After ethics committee approval was obtained, we enrolled patients who had received at least one cycle of CBC at any of three Hamburg-based TC centers. Furthermore, a matched control group of healthy, untreated patients were included in this study. Subjects were evaluated for functional and morphological retinal dysfunction. This included testing of retinal nerve fiber thickness (RNFL), color vision, and visual acuity testing in CBC recipients. Additionally, full-field electroretinograms (ff-ERG) for CBC recipients and their healthy controls were conducted. Pearson correlation coefficient analysis was carried out to assess a possible correlation between cumulative Cisplatin dose and measured RNFL and ff-ERG. Endpoints of this study were differences in test measures as well as a dose dependency on outcomes.
RESULTS: Both study groups (CBC recipients vs. healthy controls) consisted of N¼14 participants with a median patient age of 30 years (range: 22 -52 years). Seminomatous and nonseminomatous germ cell tumors were exhibited in 6 (42.85%), and 8 (57.14%) out of 14 patients, respectively. Patients had received between one to seven cycles of a CBC regimen consisting of Cisplatin, Etoposide, and Bleomycin with a median Cisplatin dose of 627mg (range: 216mg -1,205mg). The median interval between last CBC and diagnostic evaluation was 19.8 month (range: 6 -61.5 months).Morphological assessment revealed reduced RNFL in 11 of 14 patients (78.6%). While the reduction in RNFL was significantly correlated to the cumulative CBC dose received (?¼0.70; P¼0.004), it did not correlate with the time since cessation of CBC (?¼0.16; P¼0.1). ff-ERG showed significant differences between CBC recipients and the control-group in 2 of 5 tested categories (all P<0.001). Functional testing revealed no loss in visual acuity in all 14 CBC recipients, yet impaired color vision was observed in 6 of 14 patients (42.8%).
CONCLUSIONS: Our study is limited in small sample size and short-term follow-up. However, it appears that CBC in TC patients leads to short-term functional and morphological retinal alterations. Future studies should address this circumstance, as there are major implications. INTRODUCTION AND OBJECTIVES: Stress has been shown to exacerbate testicular pain and likely few personal situations are more stressful than incarceration. Our medical center manages all of the urologic complaints in the state prison population and we have anecdotally noted a large number of incarcerated men reporting genital pain and pathology (GPP). Iowa prisoners with non-emergent urologic complaints are initially evaluated with telemedicine (TM) before an in-person clinic visit. The objective of the study was to evaluate trends in urologic complaints in our male prisoner population and to determine the incidence, management, and outcomes of GPP.
Source of
METHODS: We retrospectively reviewed the medical records of all prisoners in our state who were initially evaluated by TM from Jan 2007 e Jul 2014 after obtaining IRB approval. Patient records were evaluated for urologic complaints, diagnoses, initial tests and treatments, outcomes, and eventual need for surgical treatment. GPP was defined as a primary diagnosis at the initial TM encounter of benign testicular lesion, testicular pain, or epididymitis. To determine the incidence of GPP, we queried the Iowa prison database for average numbers of male inmates per year during the study dates and compared to the frequency of prisoner visits for urologic complaints.
RESULTS: There were 376 prisoners with urologic complaints during the study period (incidence 7 per 1000 prisoner years), of which 29% (n¼110) were for GPP. Tests were ordered in 78% of men presenting with GPP on the TM encounter (73% US/radiology, 15% labs, 6% other) and medication was prescribed in 25%. Clinic visits followed TM 49% of the time. In these visits, the TM diagnosis was confirmed in 98%. Follow-up revealed that <1% had worsening of their GPP and only 9 patients (8%) ultimately required surgery (4 hydrocelectomy, 2 varicocelectomy, 1 spermatocelectomy, 1 spermatic cord block, 1 scrotal exploration). No patients were found to have testicular cancer or acute testicular torsion.
